Gasdermin D (GSDMD)

Overview

Gasdermin D (GSDMD; Wikidata: Q21119012) is a pore-forming effector protein and the principal executioner of pyroptosis, a lytic, inflammatory form of programmed cell death. It belongs to the gasdermin superfamily, which includes closely related paralogs such as Gasdermin E (GSDME) (GSDME). GSDMD is held inactive by an intramolecular clamp: an N-terminal pore-forming domain bound to a C-terminal autoinhibitory domain through a linker. Cleavage within that linker releases the constraint, and the liberated N-terminal fragment (GSDMD-N) binds acidic lipids in the inner leaflet of the plasma membrane, oligomerizes, and inserts to form a large transmembrane pore roughly 20 nm across.

Three routes cut the linker. The canonical one is the inflammatory caspase CASP1 (caspase-1), activated downstream of the NLRP3 inflammasome and other inflammasomes; the noncanonical route runs through caspase-4 and caspase-5 in humans, and caspase-11 in mice, which bind cytosolic lipopolysaccharide directly and so sense Gram-negative invasion without an upstream sensor protein; caspase-8 provides a third route under conditions that block apoptotic signaling. The resulting pores are first a conduit rather than a wound, allowing mature Interleukin-1β (IL-1β) (IL-1β) and IL18 to leave a still-intact cell — the same pores are also required for neutrophils to release extracellular traps. Sustained pore formation then draws water inward until the cell swells and ruptures, spilling damage-associated molecular patterns including High Mobility Group Box 1 (high mobility group box 1 (HMGB1)); that terminal rupture is not passive bursting but an execution step carried out by the membrane protein NINJ1.

Upstream, the toll like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-κB (NF-κB) pathway primes inflammasome components, coupling pattern recognition to eventual GSDMD cleavage. In tumors, cytolytic granzymes delivered by cytotoxic T cell populations and natural killer cell populations trigger the same death program through sibling gasdermins rather than GSDMD itself — granzyme A of the GZMA/GZMB pair cleaving GSDMB and granzyme B cleaving GSDME — which turns immunologically silent apoptosis into inflammatory death and amplifies anti-tumor immunity. This dual character, driving tissue damage in metabolic, fibrotic, autoimmune and ischemia-reperfusion disease while potentially serving anti-tumor immunity, is why GSDMD is pursued from both directions; the covalent inhibitors disulfiram, necrosulfonamide and dimethyl fumarate, each modifying the reactive cysteine required for oligomerization, are the most studied tools for blocking it.

Recent Publications Summary

Recent studies have identified Gasdermin D (GSDMD) as a critical therapeutic target in pyroptosis-driven diseases spanning inflammatory, autoimmune, infectious, and malignant pathologies. GSDMD functions as the primary executor of pyroptosis, an inflammatory cell death pathway that has emerged as a strategic target for diseases resistant to conventional apoptosis-dependent therapies. In ulcerative colitis, arctigenin inhibited GSDMD-N-mediated pyroptosis of colonic macrophages by reducing fatty acid oxidation through estrogen receptor β activation, thereby preventing GSDMD-N acetylation and oligomerization 42390841Jul. Similarly, the Tianyu traditional Chinese medicine formulation suppressed GSDMD-dependent pyroptosis in rheumatoid arthritis by modulating the NLRP3/Caspase-1/GSDMD pathway in fibroblast-like synovial cells, reducing joint inflammation 42033182Apr. In veterinary medicine, emodin attenuated Fusobacterium necrophorum-induced pyroptosis in dairy cow digital fibroblasts through NLRP3/GSDMD pathway modulation, with significant antibacterial activity against the pathogen 41819319Mar.

Biotechnological approaches have also targeted GSDMD for therapeutic benefit, particularly in chronic fibrotic and malignant diseases. In idiopathic pulmonary fibrosis, a mucus-penetrating lipid nanoparticle system delivered GSDMD-targeting small interfering RNA to the lungs, achieving enhanced lung accumulation and suppression of pyroptosis-mediated pro-fibrotic inflammation while improving pulmonary function 41985596Apr. In cancer immunotherapy, Gasdermin D cleavage by infiltrating innate lymphoid cells (ILC1s) was identified as a mechanism to induce pyroptosis in tumor cells, converting immunologically "cold" tumors into immunologically "hot" microenvironments capable of supporting robust anti-tumor immunity 41998137Apr. These findings demonstrate that both inhibition and activation of GSDMD-mediated pyroptosis can yield therapeutic benefits depending on the disease context.

The regulatory landscape of GSDMD extends beyond the canonical NLRP3/Caspase-1 axis to integrate with apoptotic pathways and metabolic circuits. GSDMD functions at the intersection of cell death modalities, with the caspase-8/GSDMD axis enabling transitions from non-inflammatory apoptotic signaling to inflammatory pyroptotic events 41490685Jan. Metabolic regulation represents an underappreciated dimension of GSDMD control: in macrophages, fatty acid oxidation promotes GSDMD-N acetylation and activation, a process reversible through pharmacological intervention 42390841Jul. Additionally, epigenetic variation in the GSDMD locus has been associated with individual responses to weight-loss interventions in childhood obesity, suggesting that GSDMD methylation status may predict metabolic intervention outcomes 42210364May.

What Changes, What Holds

1. GSDMD now looks like a context-dependent therapeutic node rather than only a downstream pyroptosis effector
NEW DIRECTION The new work broadens the baseline by showing that manipulating GSDMD can be beneficial in inflammatory, autoimmune, infectious, and malignant settings, but it does not overturn the established executioner role. It also adds a mechanistic layer: fatty acid oxidation and estrogen receptor β can regulate GSDMD-N acetylation and oligomerization, while disease-specific inhibition of the NLRP3/Caspase-1/GSDMD axis remains the main therapeutic logic 42390841Jul42033182Apr.

2. GSDMD can be therapeutically silenced or deliberately engaged depending on whether inflammation or anti-tumor immunity is the goal
NEW DIRECTION This extends the baseline by adding a delivery strategy and an immunotherapy use case, not by replacing the canonical pore-forming model. Lung-targeted siRNA suppression supports GSDMD inhibition as an anti-fibrotic approach in idiopathic pulmonary fibrosis, while tumor-cell cleavage by infiltrating ILC1s suggests that activating GSDMD-mediated pyroptosis can convert immune-cold tumors into immune-hot ones 41985596Apr41998137Apr.

3. GSDMD is regulated by apoptotic and metabolic inputs beyond the canonical inflammasome axis
NEW DIRECTION The new findings do not displace the established NLRP3/Caspase-1 pathway, but they show that the Overview’s cleavage-centered account is incomplete. Caspase-8/GSDMD coupling places GSDMD at the interface of apoptosis and pyroptosis, and fatty acid oxidation-linked acetylation adds a metabolic control point; the methylation association in childhood obesity suggests a further layer of regulation, though it remains correlative 41490685Jan42390841Jul42210364May.

Overview update candidates: disease-context-dependent therapeutic targeting; metabolic control of GSDMD-N activation; therapeutic GSDMD knockdown in fibrosis; ILC1-driven tumor pyroptosis as an immunotherapy mechanism; caspase-8/GSDMD cross-talk; metabolic regulation of GSDMD-N acetylation.